Kissei Pharmaceutical Co., Ltd. (4547.T) Stock
Kissei Pharmaceutical Co., Ltd.

Company profile
Kissei Pharmaceutical reported revenue of 88.33 billion JPY for fiscal year 2025, up 16.9% from fiscal year 2024, and net income of 11.96 billion JPY. That is a net profit margin of 13.5% for fiscal year 2025. Its largest business segment, Pharmaceuticals, brought in 80% of segment revenue in fiscal year 2025. Our analysis of its filings shows revenue growing from 67.49 billion JPY in fiscal year 2023 to 88.33 billion JPY in fiscal year 2025, 14.4% a year on average. Kissei Pharmaceutical reports about 1,786 full-time employees.
What stands out
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended March 31, 2025.
About Kissei Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, that is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0914 that is in Phase I clinical trial to treat Graves' disease; KPS-0373, that is in Phase III clinical trial to treat Spinocerebellar degeneration; KSP- 0576 that is in Phase I clinical trial to treat interstitial cystitis and bladder pain syndrome; and KSP-0930, which is in Phase I clinical trial to treat Narcolepsy. It also develops Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply food; purchases and sells related materials; and offers system development and information processing, facility and equipment management, and information gathering and development support services. Further, it engages in information equipment rentals; insurance agency business; manufactures and sells noodles; construction contracting; and computer system design and development, and cloud services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is based in Matsumoto, Japan.
Largest shareholders
- Kissei Pharmaceutical Co., Ltd.10.09%
- Brandes Investment Partners LP5.46%
- Hachijuni Nagano Bank, Ltd.4.43%
- Kanzawa Co.3.60%
- Mutsuo Kanzawa3.33 %3.33%
Share of the company, as of September 25, 2026
Leadership
- Mutsuo Kanzawa — Chairman & CEO, 76
- Keiji Miyazawa — President, COO & Director, 58
- Tetsu Takayama — Executive VP, CHRO & Director, 64
- Takahide Kitahara — GM of Financial Management Department, Executive MD & Executive Director, 63
- Yoshio Furihata — Senior Advisor & Director, 63
How much revenue does Kissei Pharmaceutical make?
Kissei Pharmaceutical reported 88.33 billion JPY in revenue for fiscal year 2025, up 16.9% from 75.58 billion JPY in fiscal year 2024.
What is Kissei Pharmaceutical's largest business segment?
Pharmaceuticals, with 75.30 billion JPY or 80% of segment revenue in fiscal year 2025. Next: Information Service Consulting) (12%) and Construction and Facility Maintenance (6%).
What companies are similar to Kissei Pharmaceutical?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sawai Group Holdings Co., Ltd. (4887.T), Nxera Pharma Co., Ltd. (4565.T), Towa Pharmaceutical Co., Ltd. (4553.T), Kaken Pharmaceutical Co., Ltd. (4521.T).
How has Kissei Pharmaceutical's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 69.04 billion JPY; FY2022, 65.38 billion JPY; FY2023, 67.49 billion JPY; FY2024, 75.58 billion JPY; FY2025, 88.33 billion JPY.
Company Information
Data as of .
How to cite: DataPorium, “Kissei Pharmaceutical Co., Ltd. (4547.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4547.T